From 1st March 2017 CEB Pharma Limited will operate as part of the Aristo Pharma Group having being acquired by the German based company, Aristo Pharma GmbH. The company has been renamed Aristo Pharma Limited and will now have access to a portfolio of products across a wide variety of therapeutic areas. Berlin based Aristo Pharma GmbH was founded in 2008 and since its inception has pursued a growth-orientated path. With headquarters in Berlin, Aristo Pharma has a multi-site European manufacturing base with locations in Germany and across Europe. The company has a heritage of excellence in both service and supply, coupled with a competitive cost base achieved through efficient manufacturing and economies of scale.
The combination of the entrepreneurial spirit within Aristo Pharma Limited, together with the capability and heritage of the broader Aristo Pharma Group, will offer the UK market cost effective generic medicines that meet the market’s demands, servicing hospital and retail sectors. Starting with a product range of Esomeprazole, Duloxetine, Quetiapine, Rasagiline and Voriconazole, growth in the product portfolio will come from products in the Aristo pipeline, legacy products and potential product acquisition. Further new product launches are planned for Summer 2017 and beyond.
Aristo Pharma Limited is committed to long term, customer focused relationships with both primary and secondary care and their respective supply chains, including wholesalers, shortliners and retail multiples. The new company will continue to be run by the existing management team of Dr Ken Williamson, John Fletcher and Ian Chatterton, who have a wealth of industry knowledge and a collective experience working across branded and generic pharmaceuticals.
For further information, please contact:
Aristo Pharma UK Ltd